Citizens JMP Reiterates a Buy Rating on CorMedix Inc. (CRMD)

Group 1 - CorMedix Inc. (NASDAQ:CRMD) is highlighted as an affordable biotech stock with a Buy rating and a price target of $22.00 set by Citizens JMP analyst Jason Butler [1] - The company completed the acquisition of Melinta Therapeutics LLC, which is expected to enhance its product offerings in innovative therapies for acute and life-threatening illnesses [2][3] - Management described the acquisition as "transformational," expanding the commercial product portfolio with seven innovative drug products and potential for near-term revenue growth [3] Group 2 - CorMedix Inc. operates as a medical device and biopharmaceutical company focused on developing and commercializing therapeutics for various diseases and medical conditions [3]